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Purpose: To characterize the differential efﬁcacy and safety of
tapentadol extended release (ER) by prior opioid experience in
patients with moderate to severe chronic osteoarthritis knee pain.
Methods: Patients were randomized to receive controlled, ad-
justable bid doses of tapentadol ER (100-250 mg), oxycodone HCl
controlled release (CR; 20-50 mg), or placebo during a 12-week
maintenance period preceded by a 3-week titration period. Pa-
tients were categorized by prior opioid use during the 3 months
before screening. Change from baseline in average pain intensity
was assessed (11-point numerical rating scale) for the overall
maintenance period. Last observation carried forward was used to
impute pain measurements that were missing after discontinuation
of treatment.
Results: Opioid-naive patients represented 67.6% of the intent-
to-treat population (n = 1,023). The least squares mean difference
(LSMD; standard error of the mean [SEM]) from baseline in aver-
age pain intensity over the maintenance period in the opioid-naive
groups was statistically superior to placebo with tapentadol ER
(-0.7 [0.21]; P=0.001) but not with oxycodone CR (-0.3 [0.21];
P=0.139). Results were similar in the opioid-experienced groups
(tapentadol ER vs placebo, LSMD [SEM] = -0.8 [0.32], P=0.014;
oxycodone CR vs placebo, LSMD [SEM] = -0.5 [0.32], P=0.101).
The rate of study discontinuation was lower in the tapentadol ER
group than in the oxycodone CR group for opioid-naive (placebo,
35.0%; tapentadol ER, 41.7%; oxycodone CR, 68.8%) and opioid-
experienced (placebo, 45.6%; tapentadol ER, 45.0%; oxycodone
CR, 55.6%) patients. Rates of discontinuation due to adverse
events (AEs) were as follows: for opioid-naive patients, placebo,
7.2%; tapentadol ER, 19.6%; oxycodone CR, 48.3%; for opioid-
experienced patients, placebo, 5.3%; tapentadol ER, 18.3%; oxy-
codone CR, 31.5%. The incidence of overall and gastrointestinal-
related treatment-emergent AEs were lower in the tapentadol ER
group than in the oxycodone CR group, regardless of prior opioid
experience (Table 1).
Conclusions: Tapentadol ER (100-250 mg bid) is an effective
analgesic treatment with better overall and gastrointestinal tolera-
bility than oxycodone CR (20-50 mg bid), regardless of prior opioid
experience.
Abstract 328 – Table 1. TEAEs by Prior Opioid Experience
Opioid-naive Opioid-experienced
Placebo Tapentadol ER Oxycodone CR Placebo Tapentadol ER Oxycodone CR
n=223 n=235 n=234 n=114 n=109 n=108
All TEAEs (%) 61.0 79.6 87.2 61.4 67.9 88.0
Gastrointestinal-related 25.6 47.7 67.5 27.2 33.0 66.7
Nervous system-related 24.2 43.4 50.0 26.3 33.0 43.5
Skin and subcutaneous tissue-related 3.1 13.6 22.2 4.4 16.5 17.6
Psychiatric-related 4.5 12.3 16.2 5.3 12.8 12.0
Musculoskeletal and connective tissue-related 17.9 9.8 9.4 16.7 11.9 13.0
TEAEs, treatment-emergent adverse events; ER, extended release; CR, controlled release.
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Purpose: To evaluate the participant acceptability of a cost-
effective novel participant diary engineered to regularly capture
relevant clinical outcomes and health economic data during the
course of a long-term clinical trial.
Methods: A novel Participant Diary was developed for participants
of a two year clinical trial evaluating the beneﬁts of glucosamine,
with or without chondroitin, in people with symptomatic knee
osteoarthritis (OA). The Participant Diary was dispatched with
the study treatment capsules every two months. The seven day
diary required the daily recording of knee pain ‘at its worst’
(rated 0-10), overall global assessment of arthritis (excellent to
poor; 0-4), participation in at least moderate physical activity for
more than 20 minutes (yes/no), use of analgesia (name; daily
